Rakuten and SBI have returned to chip into the precision immunotherapy developer’s series D round, which was led by General Catalyst.

SoftBank and Alexandria Real Estate Equities helped the Bloomberg-backed genetic medicine developer raise series C funding to further expand its pipeline of RNA therapies.

MicroPort's implantable implantable defibrillator and pacemaker spinoff has secured funding in a series C round co-led by its parent company.

Carbon-neutral blockchain technology developer Core Scientific raised $54m from Celsius while autoimmune disease therapy developer Topas Therapeutics took a BIVF-backed round past $47m.

SoftBank has contributed to a $350m private placement supporting the health screening provider's reverse takeover.

M Ventures, Novartis Venture Fund and Pfizer Ventures are among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

Denso took part in a $71m series D round for artificial intelligence technology provider Blaize while inflammatory disease drug developer Aristea closed a $63m Novo and Arena-backed round.

The newly formed RxCapital has made its first investment, in metabolic and cardiovascular disease drug developer Rivus Pharmaceuticals' $35m series A round.

Craig Cimini will be the remaining managing director at health insurer Cigna's corporate venture capital subsidiary.

SAP.io took part in email software provider Sedna's $34m series B round while Byju's picked up BCC-backed learning app developer Toppr in a deal reportedly sized at about $150m.